Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.
作者信息
Manwani Richa, Foard Darren, Mahmood Shameem, Sachchithanantham Sajitha, Lane Thirusha, Quarta Cristina, Youngstein Taryn, Rezk Tamer, Lachmann Helen J, Gillmore Julian D, Fontana Marianna, Whelan Carol, Hawkins Philip N, Wechalekar Ashutosh
机构信息
National Amyloidosis Centre, University College London (Royal Free Campus), Rowland Hill Street, London, UK.
National Amyloidosis Centre, University College London (Royal Free Campus), Rowland Hill Street, London, UK
出版信息
Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5.
Abstract
摘要
相似文献
1
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.
Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5.
2
Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population.
Blood. 2024 Aug 15;144(7):790-793. doi: 10.1182/blood.2024024623.
3
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Blood. 2019 Jan 17;133(3):215-223. doi: 10.1182/blood-2018-06-858951. Epub 2018 Oct 17.
4
Restrictive cardiomyopathy and pseudoxanthoma elasticum skin lesions.
J Cardiovasc Med (Hagerstown). 2016 Dec;17 Suppl 2:e193-e195. doi: 10.2459/JCM.0000000000000158.
5
The Real-World Data on Patients With Cardiac Stage IIIb AL Amyloidosis.
Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):694-702. doi: 10.1016/j.clml.2024.05.004. Epub 2024 May 4.
6
Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.
Blood Cancer J. 2021 Feb 1;11(2):29. doi: 10.1038/s41408-021-00412-8.
7
Impaired right ventricular function as a predictor of early mortality in patients with light‑ chain cardiac amyloidosis assessed in a cardiology department.
Pol Arch Intern Med. 2017 Dec 22;127(12):854-864. doi: 10.20452/pamw.4135. Epub 2017 Nov 3.
8
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517.
9
Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
Acta Haematol. 2020;143(5):500-503. doi: 10.1159/000504355. Epub 2020 Jan 2.
10
The critical role of chronic kidney disease in the progression of AL-amyloid cardiopathy.
Amyloid. 2019;26(sup1):109-110. doi: 10.1080/13506129.2019.1583188.
引用本文的文献
1
Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.
Sci Rep. 2025 Jul 11;15(1):25149. doi: 10.1038/s41598-025-09498-7.
2
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.
JACC Cardiovasc Imaging. 2025 May;18(5):602-617. doi: 10.1016/j.jcmg.2024.11.003. Epub 2025 Feb 21.
3
Comprehensive prognosis assessment of cardiovascular magnetic resonance parametric mapping in light chain amyloidosis.
J Cardiovasc Magn Reson. 2025;27(1):101135. doi: 10.1016/j.jocmr.2024.101135. Epub 2024 Dec 14.
4
Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.
Ann Hematol. 2025 Jan;104(1):617-625. doi: 10.1007/s00277-024-06077-0. Epub 2024 Nov 12.
5
Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.
Clin Exp Med. 2024 Nov 1;24(1):250. doi: 10.1007/s10238-024-01511-z.
6
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review.
Blood Adv. 2024 Jul 9;8(13):3464-3467. doi: 10.1182/bloodadvances.2024012737.
7
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Blood Adv. 2023 Oct 24;7(20):6080-6091. doi: 10.1182/bloodadvances.2023010324.
8
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
9
Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Haematologica. 2024 Jan 1;109(1):220-230. doi: 10.3324/haematol.2023.283325.
10
Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.
Front Cardiovasc Med. 2022 Dec 20;9:1073503. doi: 10.3389/fcvm.2022.1073503. eCollection 2022.
本文引用的文献
1
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.
2
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.
Am J Hematol. 2016 Dec;91(12):E506-E508. doi: 10.1002/ajh.24563. Epub 2016 Oct 21.
3
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15.
4
Guidelines on the management of AL amyloidosis.
Br J Haematol. 2015 Jan;168(2):186-206. doi: 10.1111/bjh.13155. Epub 2014 Oct 10.
5
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.
6
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11.
7
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5.
8
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13.
9
Amyloidosis: pathogenesis and new therapeutic options.
J Clin Oncol. 2011 May 10;29(14):1924-33. doi: 10.1200/JCO.2010.32.2271. Epub 2011 Apr 11.
10
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
J Clin Oncol. 2004 Sep 15;22(18):3751-7. doi: 10.1200/JCO.2004.03.029.
Zotero 插件